Tags

Type your tag names separated by a space and hit enter

Targeting the COX/mPGES-1/PGE2 Pathway in Neuroblastoma.
Adv Exp Med Biol. 2019; 1161:89-100.AE

Abstract

The importance of prostaglandin E2 in cancer progression is well established, but research on its role in cancer has so far mostly been focused on epithelial cancer in adults while the knowledge about the contribution of prostaglandin E2 to childhood malignancies is limited. Neuroblastoma, an extracranial solid tumor of the sympathetic nervous system, mainly affects young children. Patients with tumors classified as high-risk have poor survival despite receiving intensive treatment, illustrating a need for new treatments complimenting existing ones. The basis of neuroblastoma treatment e.g. chemotherapy and radiation therapy, target the proliferating genetically unstable tumor cells leading to treatment resistance and relapses. The tumor microenvironment is an avenue, still to a great extent, unexplored and lacking effective targeted therapies. Cancer-associated fibroblasts is the main source of prostaglandin E2 in neuroblastoma contributing to angiogenesis, immunosuppression and tumor growth. Prostaglandin E2 is formed from its precursor arachidonic acid in a two-step enzymatic reaction. Arachidonic acid is first converted by cyclooxygenases into prostaglandin H2 and then further converted by microsomal prostaglandin E synthase-1 into prostaglandin E2. We believe targeting of microsomal prostaglandin E synthase-1 in cancer-associated fibroblasts will be an effective future therapeutic strategy in fighting neuroblastoma.

Authors+Show Affiliations

Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden. Karin.Larsson@ki.se.Childhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.Childhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31562624

Citation

Larsson, Karin, et al. "Targeting the COX/mPGES-1/PGE2 Pathway in Neuroblastoma." Advances in Experimental Medicine and Biology, vol. 1161, 2019, pp. 89-100.
Larsson K, Kock A, Kogner P, et al. Targeting the COX/mPGES-1/PGE2 Pathway in Neuroblastoma. Adv Exp Med Biol. 2019;1161:89-100.
Larsson, K., Kock, A., Kogner, P., & Jakobsson, P. J. (2019). Targeting the COX/mPGES-1/PGE2 Pathway in Neuroblastoma. Advances in Experimental Medicine and Biology, 1161, 89-100. https://doi.org/10.1007/978-3-030-21735-8_9
Larsson K, et al. Targeting the COX/mPGES-1/PGE2 Pathway in Neuroblastoma. Adv Exp Med Biol. 2019;1161:89-100. PubMed PMID: 31562624.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Targeting the COX/mPGES-1/PGE2 Pathway in Neuroblastoma. AU - Larsson,Karin, AU - Kock,Anna, AU - Kogner,Per, AU - Jakobsson,Per-Johan, PY - 2019/9/29/entrez PY - 2019/9/29/pubmed PY - 2019/10/3/medline KW - COX-inhibition KW - Cancer KW - Cancer-associated fibroblasts KW - Microsomal prostaglandin E synthase-1 KW - Neuroblastoma KW - Prostaglandin E2 KW - Targeted therapy KW - Tumor microenvironment KW - Tumor-promoting inflammation KW - mPGES-1 inhibition SP - 89 EP - 100 JF - Advances in experimental medicine and biology JO - Adv. Exp. Med. Biol. VL - 1161 N2 - The importance of prostaglandin E2 in cancer progression is well established, but research on its role in cancer has so far mostly been focused on epithelial cancer in adults while the knowledge about the contribution of prostaglandin E2 to childhood malignancies is limited. Neuroblastoma, an extracranial solid tumor of the sympathetic nervous system, mainly affects young children. Patients with tumors classified as high-risk have poor survival despite receiving intensive treatment, illustrating a need for new treatments complimenting existing ones. The basis of neuroblastoma treatment e.g. chemotherapy and radiation therapy, target the proliferating genetically unstable tumor cells leading to treatment resistance and relapses. The tumor microenvironment is an avenue, still to a great extent, unexplored and lacking effective targeted therapies. Cancer-associated fibroblasts is the main source of prostaglandin E2 in neuroblastoma contributing to angiogenesis, immunosuppression and tumor growth. Prostaglandin E2 is formed from its precursor arachidonic acid in a two-step enzymatic reaction. Arachidonic acid is first converted by cyclooxygenases into prostaglandin H2 and then further converted by microsomal prostaglandin E synthase-1 into prostaglandin E2. We believe targeting of microsomal prostaglandin E synthase-1 in cancer-associated fibroblasts will be an effective future therapeutic strategy in fighting neuroblastoma. SN - 0065-2598 UR - https://www.unboundmedicine.com/medline/citation/31562624/Targeting_the_COX/mPGES_1/PGE2_Pathway_in_Neuroblastoma_ L2 - https://dx.doi.org/10.1007/978-3-030-21735-8_9 DB - PRIME DP - Unbound Medicine ER -